General Information and Variability Data of DT
DT ID DTD0006
Gene Name SLC22A2
Protein Name Organic cation transporter 2
Synonyms OCT2; SLC22A2; Solute carrier family 22 member 2; hOCT2
Gene ID
6582
UniProt ID
O15244
TCDB ID
2.A.1.19.30
DT Family Major Facilitator Superfamily (MFS)
Organic Cation Transporter (OCT) Family
Tissue Specificity primarily expressed on the renal proximal tubule cells, low expression in small intestine, trachea and bronchi, skin, placenta, brain and the choroid plexus, and the inner ear
Function This transporter is a major determinant of the anticancer activity of oxaliplatin and may contribute to antitumor specificity. Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creatinine, amantadine, memantine, acriflavine, 4-[4-(dimethylamino)-styryl]-N-methylpyridinium ASP, amiloride, metformin, N-1-methylnicotinamide (NMN), tetraethylammonium (TEA), 1-methyl-4-phenylpyridinium (MPP), cimetidine, cisplatin and oxaliplatin. Transport of creatinine is inhibited by fluoroquinolones such as DX-619 and LVFX.
Disease(s) Chronic hepatitis B infection [ICD-11: 1E51.0]
Colorectal cancer [ICD-11: 2B91]
Congestive heart failure [ICD-11: BD10]
Ovarian cancer [ICD-11: 2C73]
Parkinson's Disease [ICD-11: 8A00.0]
Partial seizures [ICD-11: 8A68.0]
Respiratory allergies [ICD-11: 4A80]
Smoking cessation [ICD-11: 6C4A.2]
Type 2 diabetes [ICD-11: 5A11]
Genetic Polymorphisms & Epigenetic Regulations of DT
Species-, Tissue- and Disease-specific Protein Abundances of DT
Exogenous Factor Altering DT Activity
Approved Drug(s) Transported by This DT Abemaciclib Drug Info Breast cancer [ICD-11: 2C60-2C6Z] Approved [1]
Amantadine Drug Info Influenza A infection [ICD-11: 1.00E+31] Approved [2]
Amiloride Drug Info High blood pressure [ICD-11: BA00] Approved [3]
Cimetidine Drug Info Acid reflux disorder [ICD-11: DA22] Approved [4]
Cisplatin Drug Info Testicular cancer [ICD-11: 2C80] Approved [5]
Clonidine Drug Info High blood pressure [ICD-11: BA00] Approved [6]
Dinoprostone Drug Info Medical abortion [ICD-11: JA00.1] Approved [7]
Dofetilide Drug Info Maintenance of normal sinus rhythm [ICD-11: BC81.3] Approved [8]
Dopamine Drug Info Parkinson's Disease [ICD-11: 8A00.0] Approved [9]
Ergotidine Drug Info Migraine [ICD-11: 8A80] Approved [10]
Famotidine Drug Info Peptic ulcer [ICD-11: DA61] Approved [11]
Gabapentin Drug Info Partial seizures [ICD-11: 8A68.0] Approved [12]
Lamivudine Drug Info Human immunodeficiency virus infection [ICD-11: 1C62.Z] Approved [13]
Memantine Drug Info Alzheimer disease [ICD-11: 8A20] Approved [2]
Metformin Drug Info Type 2 diabetes [ICD-11: 5A11] Approved [14]
Norepinephrine Drug Info Septic shock [ICD-11: 1G41] Approved [9]
Oxaliplatin Drug Info Colorectal cancer [ICD-11: 2B91] Approved [15]
Pramipexole Drug Info Parkinson's Disease [ICD-11: 8A00.0] Approved [16]
Propranolol Drug Info Migraine [ICD-11: 8A80] Approved [6]
Quinine Drug Info Malaria [ICD-11: 1F40] Approved [17]
Ranitidine Drug Info Peptic ulcer [ICD-11: DA61] Approved [11]
Varenicline Drug Info Smoking cessation [ICD-11: 6C4A.2] Approved [18]
Clinical Trial Drug(s) Transported by This DT Choline Drug Info Elderly bronchial asthma [ICD-11: CA23] Phase 3 [19]
Tetraethylammonium Drug Info Hyperlipidaemia [ICD-11: 5C8Z] Phase 2 [20]
YM155 Drug Info Non hodgkin's lymphoma [ICD-11: 2A8Z] Phase 2 [21]
Withdrawn, Discontinued or Preclinical Drug(s) Transported by This DT N-methylpyridinium Drug Info Colon cancer [ICD-11: 2B90.Z] Preclinical [22]
Prostaglandin f2Alpha Drug Info Solid tumours [ICD-11: 2D4Z] Preclinical [23]
Endogenous Substrate(s) Peptide derivatives; Organic cations
Endogenous Metabolites (EMs) Handled by This DT 1-methyl-4-phenylpyridinium EM Info Unclear experiment used for identifying this EM [24]
2-hydroxyvaleric acid EM Info Identified using the urine samples obtained from carriers of three SLC22A2 genotypes [24]
3-hydroxy-3-methylglutaric acid EM Info Identified using the urine samples obtained from carriers of three SLC22A2 genotypes [24]
5-oxoproline EM Info Identified using the urine samples obtained from carriers of three SLC22A2 genotypes [24]
Citrulline EM Info Identified using the urine samples obtained from carriers of three SLC22A2 genotypes [24]
Glucose EM Info Identified using the urine samples obtained from carriers of three SLC22A2 genotypes [24]
Haloperidol EM Info Unclear experiment used for identifying this EM [24]
Prostaglandin E2 EM Info Identified using ATCC CRL-1573 cells-OCT2h [7]
Prostaglandin F2 alpha EM Info Identified using ATCC CRL-1573 cells-OCT2h [7]
Tryptophan EM Info Identified using the urine samples obtained from carriers of three SLC22A2 genotypes [24]
Tryptophan EM Info Unclear experiment used for identifying this EM [24]
Uridine EM Info Identified using the urine samples obtained from carriers of three SLC22A2 genotypes [24]
Xanthine EM Info Identified using the urine samples obtained from carriers of three SLC22A2 genotypes [24]
Xanthosine EM Info Identified using the urine samples obtained from carriers of three SLC22A2 genotypes [24]
Drug-DT Affinity Assessed by Cell Line
Drug(s) with Drug-DT Affinity Data Amantadine Drug Info Human embryonic kidney cells (HEK293)-OCT2 Km = 27 microM [2]
Amantadine Drug Info Oocytes-OCT2 Km = 27 microM [2]
Amiloride Drug Info Human embryonic kidney cells (HEK293)-OCT2 Km = 95 microM [3]
Choline Drug Info Oocytes-OCT2 Km = 102 microM [19]
Choline Drug Info Oocytes-OCT2 Km = 210 microM [17]
Cimetidine Drug Info Human embryonic kidney cells (HEK293)-OCT2 Km = 60 microM [25]
Cimetidine Drug Info Human embryonic kidney cells (HEK293)-OCT2 Km = 72.6 microM [11]
Dinoprostone Drug Info Proximal tubule (S2) cells-OCT2 Km = 0.0289 microM [23]
Dopamine Drug Info Human embryonic kidney cells (HEK293)-OCT2 Km = 330 microM [2]
Dopamine Drug Info Human embryonic kidney cells (HEK293)-OCT2 Km = 1400 microM [9]
Dopamine Drug Info Oocytes-OCT2 Km = 390 microM [2]
Ergotidine Drug Info Human embryonic kidney cells (HEK293)-OCT2 Km = 940 microM [9]
Ergotidine Drug Info Oocytes-OCT2 Km = 1300 microM [2]
Famotidine Drug Info Human embryonic kidney cells (HEK293)-OCT2 Km = 56.1 microM [11]
Lamivudine Drug Info Oocytes-OCT2 Km = 46.3 microM [13]
Memantine Drug Info Human embryonic kidney cells (HEK293)-OCT2 Km = 34 microM [2]
Memantine Drug Info Oocytes-OCT2 Km = 34 microM [2]
Metformin Drug Info Human cervical cancer cell line (Hela)-OCT2 Km = 680 microM [26]
Metformin Drug Info Human embryonic kidney cells (HEK293)-OCT2 Km = 990 microM [14]
Metformin Drug Info Human embryonic kidney cells (HEK293)-OCT2 Km = 1072 microM [27]
Metformin Drug Info Human embryonic kidney cells (HEK293)-OCT2 Km = 3171 microM [22]
Metformin Drug Info Human embryonic kidney cells (HEK293)-OCT2 Km = 3356 microM [28]
N-methylpyridinium Drug Info Human embryonic kidney cells (HEK293)-OCT2 Km = 16 microM [2]
N-methylpyridinium Drug Info Human embryonic kidney cells (HEK293)-OCT2 Km = 19.5 microM [28]
N-methylpyridinium Drug Info Human embryonic kidney cells (HEK293)-OCT2 Km = 19.5 microM [22]
N-methylpyridinium Drug Info Oocytes-OCT2 Km = 19 microM [17]
Norepinephrine Drug Info Human embryonic kidney cells (HEK293)-OCT2 Km = 1500 microM [9]
Norepinephrine Drug Info Oocytes-OCT2 Km = 1900 microM [2]
Prostaglandin f2Alpha Drug Info Proximal tubule (S2) cells-OCT2 Km = 0.344 microM [23]
Quinine Drug Info Oocytes-OCT2 Km = 2.6 microM [17]
Ranitidine Drug Info Human embryonic kidney cells (HEK293)-OCT2 Km = 65.2 microM [11]
Serotonin Drug Info Human embryonic kidney cells (HEK293)-OCT2 Km = 290 microM [9]
Serotonin Drug Info Oocytes-OCT2 Km = 80 microM [2]
Tetraethylammonium Drug Info Human embryonic kidney cells (HEK293)-OCT2 Km = 63 microM [29]
Tetraethylammonium Drug Info Human embryonic kidney cells (HEK293)-OCT2 Km = 431 microM [29]
Tetraethylammonium Drug Info Oocytes-OCT2 Km = 33.8 microM [20]
Tetraethylammonium Drug Info Oocytes-OCT2 Km = 31 microM [17]
Tetraethylammonium Drug Info Oocytes-OCT2 Km = 76 microM [17]
Varenicline Drug Info Human embryonic kidney cells (HEK293)-OCT2 Km = 370 microM [18]
YM155 Drug Info Human embryonic kidney cells (HEK293)-OCT2 Km = 2.67 microM [21]
References
1 Abemaciclib Inhibits Renal Tubular Secretion Without Changing Glomerular Filtration Rate. Clin Pharmacol Ther. 2019 May;105(5):1187-1195.
2 Human neurons express the polyspecific cation transporter hOCT2, which translocates monoamine neurotransmitters, amantadine, and memantine. Mol Pharmacol. 1998 Aug;54(2):342-52.
3 Characterization of regulatory mechanisms and states of human organic cation transporter 2. Am J Physiol Cell Physiol. 2006 Jun;290(6):C1521-31.
4 Elevated systemic elimination of cimetidine in rats with acute biliary obstruction: the role of renal organic cation transporter OCT2. Drug Metab Pharmacokinet. 2010;25(4):328-34.
5 Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol. 2005 Dec;167(6):1477-84.
6 Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145.
7 Are organic cation transporters capable of transporting prostaglandins? Naunyn Schmiedebergs Arch Pharmacol. 2005 Aug;372(2):125-30.
8 FDA Drug Development and Drug Interactions
9 Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain. Neuropharmacology. 2006 Jun;50(8):941-52.
10 The organic cation transporters (OCT1, OCT2, EMT) and the plasma membrane monoamine transporter (PMAT) show differential distribution and cyclic expression pattern in human endometrium and early pregnancy decidua. Mol Reprod Dev. 2007 Oct;74(10):1303-11.
11 A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J Pharmacol Exp Ther. 2005 Oct;315(1):337-45.
12 Clinical pharmacokinetic drug interaction studies of gabapentin enacarbil, a novel transported prodrug of gabapentin, with naproxen and cimetidine. Br J Clin Pharmacol. 2010 May;69(5):498-507.
13 Genetic variants of organic cation transporter 1 (OCT1) and OCT2 significantly reduce lamivudine uptake. Biopharm Drug Dispos. 2012 Apr;33(3):170-8.
14 Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet. 2005 Oct;20(5):379-86.
15 Relevance of copper transporter 1 and organic cation transporters 1-3 for oxaliplatin uptake and drug resistance in colorectal cancer cells. Metallomics. 2018 Mar 1;10(3):414-425.
16 Uptake of pramipexole by human organic cation transporters. Mol Pharm. 2010 Aug 2;7(4):1342-7.
17 Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol. 1997 Jul;16(7):871-81.
18 Effect of human renal cationic transporter inhibition on the pharmacokinetics of varenicline, a new therapy for smoking cessation: an in vitro-in vivo study. Clin Pharmacol Ther. 2008 Apr;83(4):567-76.
19 Ventricular choline transport: a role for organic cation transporter 2 expressed in choroid plexus. J Biol Chem. 2001 Nov 9;276(45):41611-9.
20 Molecular mechanisms of organic cation transport in OCT2-expressing Xenopus oocytes. Biochim Biophys Acta. 1999 Mar 4;1417(2):224-31.
21 Characterization of human organic cation transporter 1 (OCT1/SLC22A1)- and OCT2 (SLC22A2)-mediated transport of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)- 4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel small molecule survivin suppressant. Drug Metab Dispos. 2010 Jan;38(1):1-4.
22 Functional characterization of the human organic cation transporter 2 variant p.270Ala>Ser. Drug Metab Dispos. 2009 Jun;37(6):1312-8.
23 Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. J Pharmacol Exp Ther. 2002 Apr;301(1):293-8.
24 Pharmacogenetics meets metabolomics: discovery of tryptophan as a new endogenous OCT2 substrate related to metformin disposition. PLoS One. 2012;7(5):e36637.
25 Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
26 Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms. Am J Physiol Renal Physiol. 2010 Apr;298(4):F997-F1005.
27 Effects of tetraalkylammonium compounds with different affinities for organic cation transporters on the pharmacokinetics of metformin. Biopharm Drug Dispos. 2007 Dec;28(9):501-10.
28 Structural determinants of inhibitor interaction with the human organic cation transporter OCT2 (SLC22A2). Naunyn Schmiedebergs Arch Pharmacol. 2009 Apr;379(4):337-48.
29 cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney. J Am Soc Nephrol. 2002 Jul;13(7):1703-10.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.